Prevent
Advancing the science that stops age-related disease before it establishes — hormetic conditioning, metabolic resilience and early biological-age measurement.
• About the foundation
The UK's oldest
longevity charity
Prevent · Restore · Preserve
Founded in 2008, the Biogerontology Research Foundation uses the power of science to alleviate suffering through preventive and restorative medicine — advancing the scientific R&D and social-impact work behind practical longevity, mitochondrial medicine and global health.
• Founded 2008
• Registered UK charity
• WHO ICD-11 XT9T
• 1,100+ report pages
• Our mission
Three commitments that define the charity
Everything the Foundation funds and publishes traces back to one of three commitments.
Restore
Restoring cellular function where damage has already occurred, through controlled oxygen modulation and mitochondrial medicine.
Preserve
Preserving healthspan at population scale by translating validated protocols into accessible, real-world care.
• Our approach
Science first, translation always
MechanismEstablish the cellular basis
ProtocolDesign and test the intervention
EvidenceTrial, measure and publish
TranslationInto clinics and communities
The Foundation is deliberately small and scientific rather than administrative. We concentrate on the mechanistic questions others skip past, then work with delivery partners to carry validated science into practice.
• A world first
We helped open the door to treating ageing as a disease
The Foundation's most consequential contribution to longevity science was regulatory, not laboratory.
In 2018, together with the International Longevity Alliance, the Biogerontology Research Foundation successfully contributed to the addition of a new World Health Organization-approved extension code — XT9T, “ageing-related” — during the ICD-11 revision.
Because ICD codes are a prerequisite for the registration of new drugs and therapies, recognising ageing as a pathological process removes a fundamental regulatory obstacle to therapeutic and preventive strategies targeting ageing and age-related disease.
- A joint proposal to the WHO ICD-11 Task Force, co-authored by the Foundation
- Recognised as a landmark by The Lancet in a 2018 editorial
• Our science
Three frontiers where our research leads
The Foundation's research agenda concentrates on the intersection of hypoxia, mitochondrial medicine and extreme environments — the science underlying practical longevity and its translation to global health.
IHHT, IHT & HBOT research
Comprehensive study, testing and optimisation of intermittent hypoxic-hyperoxic training machines and protocols — their composition, their limits and the routes to improvement.
- Device and protocol research
- Advanced HSI2T protocol
Mitochondrial medicine
The cellular science of controlled oxygen modulation and mitochondrial hormesis — the mechanistic foundation for healthspan and hard-to-treat disease.
- Hormesis and biogenesis
- Immune rebalancing
Pet rejuvenation study
A multi-university UAE veterinary trial testing whether IHHT, HBOT and their combination improve healthspan and biological-age biomarkers in aged dogs and cats.
- Breed-diverse four-arm design
- Run with the Oxy Wave Foundation
• Our history
A heritage of world-firsts in longevity science
2008
FoundedLaunched as a UK non-profit by prominent longevity scientists2018
WHO XT9TJointly secured the WHO-approved ageing-related extension2020s
Landscape reportsComprehensive overviews of the global longevity industryToday
Applied R&DDevices, protocols and translational trials2008Established
Founded as a UK charity by longevity scientists
XT9TWHO ICD-11
Ageing-related extension code secured in 2018
1,100+Report pages
Landscape analysis of the global longevity sector
3R&D priorities
Devices, mechanism and translational trials
• Governance
Directed by scientists, not administrators
A deliberately lean board
The Foundation keeps its governing body small so that scientific judgement drives the research agenda. Delivery capacity is added through partnerships rather than headcount.
- Trustees hold fiduciary control and set the research priorities
- Scientific advisors validate mechanism, protocol and clinical claims
- Delivery partners supply engineering, clinical and deployment capacity
Board of Trustees
Scientific Advisory Board
Research Programmes
Delivery Partners
People
Trustees & scientific advisors
Entrepreneur, venture philanthropist and investor, involved in longevity and aging research since 2014.
Full profile →
Coordinates research direction, publications and programme delivery.
Full profile →
Trustee since 2025, after more than a decade supporting the Foundation's policy work as a volunteer.
Full profile →
Pioneer of hypoxic training in mitochondria medicine and creator of the MITOPRO protocol.
Full profile →• Partnership
Working across the longevity ecosystem
The Foundation's research reaches practice through long-standing partnerships and international collaborations.
Oxy Wave Foundation
Operationalises IHHT and structured breathwork into deployable programmes; the Foundation is its scientific anchor for translational ageing.
Longevity.Group
Brings validated science into clinics, members and real-world longevity infrastructure.
Coalitions & associations
Collaborating foundations and associations across the UK, Israel, Canada and Europe on longevity policy and research.
• Support the science
Support the science of healthy longevity
Partner on a research programme, collaborate on a trial, or support our mission to alleviate suffering through preventive and restorative medicine.